Upadacitinib and Risankizumab Show Comparable Remission in Crohn’s Disease After Anti-TNF Failure
A retrospective study found comparable corticosteroid-free remission with upadacitinib and risankizumab in anti-TNF-exposed Crohn’s patients. Upadacitinib showed higher endoscopic remission at week 52 but more adverse events. Both JAK and IL-23 inhibitors are shaping the growing IBD treatment market.